News & Updates
Find A Specialist
Resource Finder at Kennedy Krieger Institute
A free resource that provides access to information and support for individuals and families living with developmental disabilities.
Michael Shamblott, Ph.D.
Kennedy Krieger Institute
707 N. Broadway, Suite 520
Baltimore, MD 21205
Phone: (443) 923-9227
Dr. Michael Shamblott is a research scientist at the International Center for Spinal Cord Injury (ICSCI) at Kennedy Krieger Institute. He is also an assistant professor with the Johns Hopkins School of Medicine, Department of Neurology, and has a joint appointment in the Johns Hopkins University Department of Chemical and Biological Engineering.
Dr. Shamblott earned his doctorate of philosophy in molecular and cell biology in 1995 from the University Maryland, Baltimore County (UMBC). From 1989 to 1995, while at UMBC, he worked as a research assistant in the Department of Cellular and Molecular Biology. From there, he became a post-doctoral fellow at the Johns Hopkins School of Medicine until 1999. In 2000, he was appointed as an assistant professor at the Johns Hopkins School of Medicine, Department of Gynecology and Obstetrics. Joining the International Center of Spinal Cord Injury in 2008, Dr. Shamblott became a research scientist at the Hugo W. Moser Research Institute at Kennedy Krieger Institute in the International Center for Spinal Cord Injury, switching his primary appointment to the Department of Neurology at the Johns Hopkins School of Medicine.
Dr. Shamblott has received the Pre-doctoral Fellowship Award from the Office of Naval Research and the Alfred Blalock Research Award from the Johns Hopkins University School of Medicine. In 2002, he received the Mary Tyler Moore and S. Robert Levine Clinical Career Development Award from the Juvenile Diabetes Research Foundation, and, in 2004, he was awarded the Giles W. and Elise G. Mead Foundation Award.
Dr. Shamblott’s research focuses on applications of human stem and progenitor cells. He is currently involved in research to develop cell therapies for type I (juvenile) diabetes and spinal cord injury.
- 1 of 2